IN8bio to Present at Cantor Oncology & HemOnc Conference
IN8bio, a clinical-stage biopharmaceutical company, announced that CEO William Ho will speak at the “Cell Therapy in Solid Tumors” panel during the Cantor Oncology & HemOnc Conference on September 28, 2022, at 1:45 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IN8bio, a clinical-stage biopharmaceutical company, announced that CEO William Ho will speak at the “Cell Therapy in Solid Tumors” panel during the Cantor Oncology & HemOnc Conference on September 28, 2022, at 1:45 p.m. ET. IN8bio is focused on developing innovative gamma-delta T cell therapies for solid and liquid tumors through its DeltEx platform. The company is conducting Phase 1 clinical trials for INB-200, targeting newly diagnosed glioblastoma, and INB-100 for leukemia patients undergoing stem cell transplantation, alongside its preclinical programs.
Details
News Market Reaction – INAB
The recorded move for INAB in the trading session of this news was +1.12%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced that William Ho, IN8bio’s Chief Executive Officer, will be a speaker on the “Cell Therapy in Solid Tumors” panel at the Cantor Oncology & HemOnc Conference. The panel will take place at 1:45 p.m. ET on September 28, 2022.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop cell therapies that synergize with chemotherapy to effectively identify and eradicate tumor cells.
IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types. For more information about IN8bio and its programs, please visit www.IN8bio.com.
Company Contact:
IN8bio, Inc.
Patrick McCall
+ 1 646.600.6GDT (6438)
info@IN8bio.com
Investors & Media Contact:
Argot Partners
IN8bio@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.